Список литературы

Поставить закладку

Glynne-Jones R., Nilsson P.J., Aschele C., Goh V., Peiffert D., Cervantes A., Arnold D.; European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 2014;40(10):1165–76.
Hoots B.E., Palefsky J.M., Pimenta J.M., Smith J.S. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124(10):2375–83.
Nelson V.M., Benson A.B. 3rd. Epidemiology of Anal Canal Cancer. Surg Oncol Clin N Am 2017;26(1):9–15.
DeVita V.T., Lawrence T.S., Rosenberg S.A. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Wolters Kluwer/Lippincott Williams & Wilkins, 2008.
Correa J.C., Cummings B., Easson A.M. Anal Cancer. Surgical Oncology Manual. Springer, 2016. P. 21–39.
Minsky B.D., Guillem J.G. Neoplasms of the anus. Holland‐Frei Cancer Medicine 2016:1–12.
Henkenberens C., Toklu H., Tamme C., Bruns F. Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer – A Single-Center Retrospective Analysis. Anticancer Res 2016;36(6):3173–7.
Williams M., Swampillai A., Osborne M., Mawdsley S., Hughes R., Harrison M., Harvey R., Glynne-Jones R.; Mount Vernon Colorectal Cancer Network. Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin. Cancer 2013;119(13):2391–8.
Reginelli A., Granata V., Fusco R., Granata F., Rega D., Roberto L., Pellino G., Rotondo A., Selvaggi F., Izzo F., Petrillo A., Grassi R. Diagnostic performance of magnetic resonance imaging and 3D endoanal ultrasound in detection, staging and assessment post treatment, in anal cancer. Oncotarget 2017;8(14):22980–90.
Granata V., Fusco R., Reginelli A., Roberto L., Granata F., Rega D., Rotondo A., Grassi R., Izzo F., Petrillo A. Radiological assessment of anal cancer: an overview and update. Infect Agent Cancer 2016;11:52.
Mistrangelo M., Franco P., Testa V., Lesca A., Bellò M., Morino M. Sentinel Node Biopsy for Anal Carcinoma. Clin Oncol 2017;2:1311.
Van den Wyngaert T., Strobel K., Kampen W.U., Kuwert T., van der Bruggen W., Mohan H.K., Gnanasegaran G., Delgado-Bolton R., Weber W.A., Beheshti M., Langsteger W., Giammarile F., Mottaghy F.M., Paycha F.; EANM Bone & Joint Committee and the Oncology Committee. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016;43(9):1723–38.
Starck S.Å., Rosendahl L. Comments on Van den Wyngaert et al., The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016;43(12):2263–4.
Glynne-Jones R., Meadows H., Wan S., Gollins S., Leslie M., Levine E., McDonald A.C., Myint S., Samuel L., Sebag-Montefiore D. EXTRA – a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 2008;72(1):119–26.
Meulendijks D., Dewit L., Tomasoa N.B., van Tinteren H., Beijnen J.H., Schellens J.H., Cats A. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 2014;111(9):1726–33.
Gunderson L.L., Winter K.A., Ajani J.A., Pedersen J.E., Moughan J., Benson A.B. 3rd, Thomas C.R. Jr., Mayer R.J., Haddock M.G., Rich T.A., Willett C.G. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 2012;30(35):4344–51.
James R.D., Glynne-Jones R., Meadows H.M., Cunningham D., Myint A.S., Saunders M.P., Maughan T., McDonald A., Essapen S., Leslie M., Falk S., Wilson C., Gollins S., Begum R., Ledermann J., Kadalayil L., Sebag-Montefiore D. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 2013;14(6):516–24.
Myerson R.J., Garofalo M.C., El Naqa I., Abrams R.A., Apte A., Bosch W.R., Das P., Gunderson L.L., Hong T.S., Kim J.J., Willett C.G., Kachnic L.A. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74(3):824–30.
Mitra D., Hong T.S., Horick N., Rose B., Drapek L.N., Blaszkowsky L.S., Allen J.N., Kwak E.L., Murphy J.E., Clark J.W., Ryan D.P., Cusack J.C., Bordeianou L.G., Berger D.L., Wo J.Y. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose- painted IMRT per RTOG 0529. Adv Radiat Oncol 2017;2(2):110–7.
Wright J.L., Patil S.M., Temple L.K., Minsky B.D., Saltz L.B., Goodman K.A. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys 2010;78(4):1064–72.
Bazan J.G., Hara W., Hsu A., Kunz P.A., Ford J., Fisher G.A., Welton M.L., Shelton A., Kapp D.S., Koong A.C., Goodman K.A., Chang D.T. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011;117(15):3342–51.
Dewas C.V., Maingon P., Dalban C., Petitfils A., Peignaux K., Truc G., Martin E., Khoury C., Dewas S., Créhange G. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? Radiat Oncol 2012;7:201.
Lee A., Albert A., Sheth N., Adedoyin P., Rowley J., Schreiber D. Patterns of care and outcomes of intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for anal cancer. J Gastrointest Oncol 2019;10(4):623–31.
Ghareeb A., Paramasevon K., Mokool P., van der Voet H., Jha M. Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy. Ann R Coll Surg Engl 2019;101(3):168–75.
Ortholan C., Resbeut M., Hannoun-Levi J.M., Teissier E., Gerard J.P., Ronchin P., Zaccariotto A., Minsat M., Benezery K., François E., Salem N., Ellis S., Azria D., Champetier C., Gross E., Cowen D. Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys 2012;82(5):1988–95.
Matthews J.H., Burmeister B.H., Borg M., Capp A.L., Joseph D., Thompson K.M., Thompson P.I., Harvey J.A., Spry N.A. T1-2 anal carcinoma requires elective inguinal radiation treatment – the results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol 2011;98(1):93–8.
Zilli T., Betz M., Bieri S., Ris F., Roche B., Roth A.D., Allal A.S. Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. Int J Radiat Oncol Biol Phys 2013;87(1):60–6.
Janssen S., Meier zu Eissen J., Kolbert G., Bremer M., Karstens J.H., Meyer A. Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome. Int J Colorectal Dis 2009;24(12):1421–8.
Meyer A., Meier Zu Eissen J., Karstens J.H., Bremer M. Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome. Acta Oncol 2006;45(6):728– 35.
Konski A., Garcia M. Jr., John M., Krieg R., Pinover W., Myerson R., Willett C. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008;72(1):114–8.
Rao S., Sclafani F., Guren M.G., Adams R.A., Montefiori D., Segelov E., Bryant A., Peckitt C., Roy A., Seymour M.T. InterAACT: a multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease-an international rare cancers initiative (IRCI) trial. Ann Oncol 2018;29.
Faivre C., Rougier P., Ducreux M., Mitry E., Lusinchi A., Lasser P., Elias D., Eschwege F. Carcinome épidermoïde métastatique de l"anus: étude rétrospective de l’efficacité de l’association de 5-fluoro-uracile en perfusion continue et de cisplatine [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer 1999;86(10):861– 5.
Mondaca S.N., Chatila W.K., Hechtman J.F., Bates D., Cercek A., Segal N.H., Stadler Z.K., Varghese A.M., Berger M.F., Capanu M. FOLFCIS regimen for treatment of cancer of the anal canal. American Society of Clinical Oncology, 2018.
Kim S., Jary M., André T., Vendrely V., Buecher B., François E., Bidard F.-C., Dumont S., Samalin E., Peiffert D., Pernot S., Baba-Hamed N., El Hajbi F., Bouché O., Desrame J., Parzy A., Zoubir M., Louvet C., Bachet J.B., Nguyen T., Abdelghani M.B., Smith D., De La Fouchardière C., Aparicio T., Bennouna J., Gornet J.M., Jacquin M., Bonnetain F., Borg C. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). BMC Cancer 2017;17(1):574.
Morris V.K., Salem M.E., Nimeiri H., Iqbal S., Singh P., Ciombor K., Polite B., Deming D., Chan E., Wade J.L., Xiao L., Bekaii-Saab T., Vence L., Blando J., Mahvash A., Foo W.C., Ohaji C., Pasia M., Bland G., Ohinata A., Rogers J., Mehdizadeh A., Banks K., Lanman R., Wolff R.A., Streicher H., Allison J., Sharma P., Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(4):446–53.
Ott P.A., Piha-Paul S.A., Munster P., Pishvaian M.J., van Brummelen E.M.J., Cohen R.B., Gomez-Roca C., Ejadi S., Stein M., Chan E., Simonelli M., Morosky A., Saraf S., Emancipator K., Koshiji M., Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28(5):1036– 41.
Grifaichi F., Padovani A., Romeo F., Trinca C., Moscetti L., Cortesi E. Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. Tumori 2001;87(1):58–9.
Lukan N., Strobel P., Willer A., Kripp M., Dinter D., Mai S., Hochhaus A., Hofheinz R.D. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 2009;77(5):293–9.
Barmettler H., Komminoth P., Schmid M., Duerr D. Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer. Case Rep Oncol 2012;5(2):428– 33.
Rogers J.E., Ohinata A., Silva N.N., Mehdizadeh A., Eng C. Epidermal growth factor receptor inhibition in metastatic anal cancer. Anticancer Drugs 2016;27(8):804–8.
Kim D.W., Byer J., Kothari N., Mahipal A., Chang Y.D., Kim R.D. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology 2017;92(4):190–6.
Mullen J.T., Rodriguez-Bigas M.A., Chang G.J., Barcenas C.H., Crane C.H., Skibber J.M., Feig B.W. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 2007;14(2):478–83.
Glynne-Jones R., Sebag-Montefiore D., Meadows H.M., Cunningham D., Begum R., Adab F., Benstead K., Harte R.J., Stewart J., Beare S., Hackshaw A., Kadalayil L.; ACT II study group. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 2017;18(3):347–56.
Cummings B.J., Keane T.J., O’Sullivan B., Wong C.S., Catton C.N. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991;21(5):1115–25.
Schlienger M., Krzisch C., Pene F., Marin J.L., Gindrey-Vie B., Mauban S., Barthelemy N., Habrand J.L., Socie G., Parc R., et al. Epidermoid carcinoma of the anal canal treatment results and prognostic variables in a series of 242 cases. Int J Radiat Oncol Biol Phys 1989;17(6):1141–51.
Brown S.R., Skinner P., Tidy J., Smith J.H., Sharp F., Hosie K.B. Outcome after surgical resection for high-grade anal intraepithelial neoplasia (Bowen’s disease). Br J Surg 1999;86(8):1063–6.
Marchesa P., Fazio V.W., Oliart S., Goldblum J.R., Lavery I.C. Perianal Bowen’s disease: a clinicopathologic study of 47 patients. Dis Colon Rectum 1997;40(11):1286–93.
Polcz M., Chakravarthy A.B., Bailey C.E. Diagnosis and Management of Perianal Skin Tumors. Anal Cancer. Springer, 2019. P. 123–131.
Isik O., Aytac E., Brainard J., Valente M.A., Abbas M.A., Gorgun E. Perianal Paget’s disease: three decades experience of a single institution. Int J Colorectal Dis 2016;31(1):29–34.
Kachnic L.A., Winter K., Myerson R.J., Goodyear M.D., Willins J., Esthappan J., Haddock M.G., Rotman M., Parikh P.J., Safran H., Willett C.G. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86(1):27–33.
Ajani J.A., Winter K.A., Gunderson L.L., Pedersen J., Benson A.B. 3rd, Thomas C.R. Jr., Mayer R.J., Haddock M.G., Rich T.A., Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299(16):1914–21.
Yeung R., McConnell Y., Roxin G., Banerjee R., Urgoiti G.B., MacLean A.R., Buie W.D., Mulder K.E., Vickers M.M., Joseph K.J., Doll C.M. One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity. Curr Oncol 2014;21(3):e449–56.
Silver J.K., Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2013;92(8):715–27.
Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery. Int J Surg 2017;39:156–62.
Gillis C., Li C., Lee L., Awasthi R., Augustin B., Gamsa A., Liberman A.S., Stein B., Charlebois P., Feldman L.S., Carli F. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. Anesthesiology 2014;121(5):937–47.
Tsimopoulou I., Pasquali S., Howard R., Desai A., Gourevitch D., Tolosa I., Vohra R. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015;22(13):4117–23.
Li P., Fang F., Cai J.X., Tang D., Li Q.G., Wang D.R. Fast-track rehabilitation vs conventional care in laparoscopic colorectal resection for colorectal malignancy: a meta-analysis. World J Gastroenterol 2013;19(47):9119–26.
Wren S.M., Martin M., Yoon J. K., Bech F. Postoperative pneumonia-prevention program for the inpatient surgical ward. J Am Coll Surg 2010;210(4):491–5.
de Almeida E.P.M., de Almeida J.P., Landoni G., Galas F.R.B.G., Fukushima J.T., Fominskiy E., de Brito C.M.M., Cavichio L.B.L., de Almeida L.A.A., Ribeiro U. Jr., Osawa E.A., Diz M.P., Cecatto R.B., Battistella L.R., Hajjar L.A. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial. Br J Anaesth 2017;119(5):900–7.
Visser W.S., Te Riele W.W., Boerma D., van Ramshorst B., van Westreenen H.L. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review. Ann Coloproctol 2014;30(3):109–14.
Finnane A., Janda M., Hayes S.C. Review of the evidence of lymphedema treatment effect. Am J Phys Med Rehabil 2015;94(6):483–98.
Cheville A.L., Kollasch J., Vandenberg J., Shen T., Grothey A., Gamble G., Basford J.R. A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage 2013;45(5):811–21.
Jeon J., Sato K., Niedzwiecki D., Ye X., Saltz L.B., Mayer R.J., Mowat R.B., Whittom R., Hantel A., Benson A., Wigler D.S., Atienza D., Messino M., Kindler H., Venook A., Fuchs C.S., Meyerhardt J.A. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 2013;12(4):233–8.
Mustian K.M., Alfano C.M., Heckler C., Kleckner A.S., Kleckner I.R., Leach C.R., Mohr D., Palesh O.G., Peppone L.J., Piper B.F., Scarpato J., Smith T., Sprod L.K., Miller S.M. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis. JAMA Oncol 2017;3(7):961–8.
Kinkead B., Schettler P.J., Larson E.R., Carroll D., Sharenko M., Nettles J., Edwards S.A., Miller A.H., Torres M.A., Dunlop B.W., Rakofsky J.J., Rapaport M.H. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer 2018;124(3):546–54.
Bensadoun R.J., Nair R.G. Low-Level Laser Therapy in the Management of Mucositis and Dermatitis Induced by Cancer Therapy. Photomed Laser Surg 2015;33(10):487–91.
Mandard A.-M., Dalibard F., Mandard J.-C., Marnay J., Henry-Amar M., Petiot J.-F., Gignoux M. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994;73(11):2680–6.
Hoffman R., Welton M.L., Klencke B., Weinberg V., Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999;44(1):127–31.
John M., Pajak T., Flam M., Hoffman J., Markoe A., Wolkov H., Paris K. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996;2(4):205– 11.
Wexler A., Berson A.M., Goldstone S.E., Waltzman R., Penzer J., Maisonet O.G., McDermott B., Rescigno J. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 2008;51(1):73–81.
Edelman S., Johnstone P.A. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys 2006;66(1):206–11.
Kouloulias V., Plataniotis G., Kouvaris J., Dardoufas C., Gennatas C., Uzunoglu N., Papavasiliou C., Vlahos L. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 2005;28(1):91–9.
Ott O.J., Schmidt M., Semrau S., Strnad V., Matzel K.E., Schneider I., Raptis D., Uter W., Grützmann R., Fietkau R. Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Strahlenther Onkol 2019;195(7):607–14.
Leon O., Guren M., Hagberg O., Glimelius B., Dahl O., Havsteen H., Naucler G., Svensson C., Tveit K.M., Jakobsen A., Pfeiffer P., Wanderås E., Ekman T., Lindh B., Balteskard L., Frykholm G., Johnsson A. Anal carcinoma – Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiother Oncol 2014;113(3):352–8.
Freshwater T., Kondic A., Ahamadi M., Li C.H., de Greef R., de Alwis D., Stone J.A. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017;5:43.
Marabelle A., Cassier P.A., Fakih M., Kao S., Nielsen D., Italiano A., Guren T.K., van Dongen M.G.J., Spencer K., Bariani G.M., Ascierto P.A., Santoro A., Shah M., Asselah J., Iqbal S., Takahashi S., Piha-Paul S.A., Ott P.A., Chatterjee A., Jin F., Norwood K., Delord J.P. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non- randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol 2022;7(5):446–54.
Bei D., Osawa M., Uemura S., Ohno T., Gobburu J., Roy A., Hasegawa M. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. Cancer Sci 2020;111(2):528–35.
De Dosso S., Martin V., Zanellato E., Frattini M., Saletti P. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori 2010;96(4):627–8.
Phan L.K., Hoff P.M. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum 2007;50(3):395–8.
Tabernero J., Pfeiffer P., Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008;13(2):113–9.
Parikh A.R., Gonzalez-Gugel E., Smolyakova N., Jen M.H., Toms N., Lin Y., Kim J.S., Kopetz S. Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis. Oncologist 2022;27(5):371–9.
Addeo R., Montella L., Mastella A., Vincenzi B., Mazzone S., Ricciardiello F., Del Prete S. Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. Oncology 2018;95(6):353–9.
Czejka M., Gruenberger B., Kiss A., Farkouh A., Schueller J. Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer. Anticancer Res 2010;30(6):2355–60.
Tabernero J., Ciardiello F., Rivera F., Rodriguez-Braun E., Ramos F.J., Martinelli E., Vega-Villegas M.E., Roselló S., Liebscher S., Kisker O., Macarulla T., Baselga J., Cervantes A. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 2010;21(7):1537–45.